Physician profile
Merry Perry
NPI 1982718318
$1,879.45
in general payments reported to CMS, 2019-2025
13 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.13 · 2022: $195 · 2023: $396 · 2024: $652 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.44 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $564.12 | 2023-2025 | Epclusa, Biktarvy |
| Viiv Healthcare Company | $483.29 | 2022-2025 | Apretude, Dovato, Rukobia |
| Merck Sharp & Dohme LLC | $223.35 | 2021-2025 | Pifeltro, Delstrigo, Isentress |
| Theratechnologies INC. | $156.10 | 2023-2024 | Egrifta Sv, Trogarzo, Egrifta |
| Abbvie INC. | $142.92 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.97 | 2024 | |
| Novartis Pharmaceuticals Corporation | $71.97 | 2022-2023 | |
| Novo Nordisk INC | $49.42 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $29.97 | 2025 | Repatha, Otezla |
| Vbi Vaccine (Delaware) INC. | $19.56 | 2022 | |
| Janssen Biotech, INC. | $17.18 | 2023 | Symtuza |
| Lilly USA, LLC | $15.77 | 2025 | Mounjaro |
| Exact Sciences Corporation | $13.83 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merry Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.